Get to know our clinical trials
Ensayo de ALXN2220 en pacietnes adultos con amiloidosis cardiaca por transtirretina
WE CONDUCTED THIS TRIAL TO LEARN MORE ABOUT AN EXPERIMENTAL DRUG CALLED ALXN2220 FOR THE TREATMENT OF ADULT PATIENTS WITH TRANSTHYRETIN CARDIAC AMYLOIDOSIS, AND ALSO TO BETTER UNDERSTAND THE DISEASE STUDIED AND THE ASSOCIATED HEALTH PROBLEMS.
Technical Summary
- PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF THE AMYLOID DEPLETING AGENT ALXN2220 IN ADULT PARTICIPANTS WITH TRANSTHYRETIN CARDIAC AMYLOIDOSIS (ATTR-CM).
- Code EudraCT: 2023-506669-70
- Protocol number: ALXN2220-ATTR-CM-301
- Promoter: Alexion Pharmaceuticals, Inc.
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
Who can participate?
Trial of ALXN2220 in adult participants with transthyretin cardiac amyloidosis
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.